Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial
Sylvie Bonvalot(Dana-Farber Cancer Institute), Rick L. Haas(Leiden University Medical Center), Marco Fiore(Fondazione IRCCS Istituto Nazionale dei Tumori), Angelo Paolo Dei Tos(University of Padua), Hans Gelderblom(Leiden University Medical Center), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Frits van Coevorden(The Netherlands Cancer Institute), Antonino De Paoli(Centro di Riferimento Oncologico), Chandrajit P. Raut(Dana-Farber Cancer Institute), Stephan Stoldt(Oslo University Hospital), D. Strauß(Royal Marsden Hospital), Sandrine Marréaud(European Organisation for Research and Treatment of Cancer), Charles Honoré(Institut Gustave Roussy), Aisha Miah(Institute of Cancer Research), Daphne Hompes, Claudia Sangalli(Fondazione IRCCS Istituto Nazionale dei Tumori), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Pierre Méeus(Centre Léon Bérard), Marco Rastrelli(Istituti di Ricovero e Cura a Carattere Scientifico), Eberhard Stoeckle(Institut Bergonié), Jean‐Jacques Stelmes(European Organisation for Research and Treatment of Cancer), Saskia Litière(European Organisation for Research and Treatment of Cancer), Peter Chung(Princess Margaret Cancer Centre), C. Le Péchoux(Institut Gustave Roussy), Elizabeth H. Baldini(Dana-Farber Cancer Institute), Carol J. Swallow(University Health Network)
Cited by 482
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Cremophor EL
|European Journal of Cancer|2001|1.6k